Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (June 2020)
18 slides from Cynata Therapeutics's investor presentation, Jun 10, 2020
Slide 1: Cynata Investor Presentation ASX Announcement
ASX ANNOUNCEMENT 10 June 2020 Cynata Investor Presentation For personal use only Melbourne, Australia; 10 June 2020: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today released a new investor prese
Slide 2: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited June 2020
Slide 3: Important Information
Important Information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 4: Cynata Therapeutics is a Phase II-ready biotech with a scalable stem cell platform
Cynata Therapeutics is a Phase II-ready biotech with a highly scalable, proprietary platform for developing stem cell therapeutics For personal use only Our focus Financial information Share price (9-June-20) A$0.665 Utilise our proprietary CymerusTM platform technology to develop commercially scala
Slide 5: Recent Developments: Optimising Phase 2 clinical programs
Recent Developments: Optimising Phase 2 clinical programs For personal use only Ethics approval for COVID-19 clinical Progressing clinical COVID-19 clinical trial development strategy development Accelerated planning and rapidly Assessing opportunities to expand FUJIFILM endorsement via li
Slide 6: MSCs have potential utility in complications arising from COVID-19 infection
MSCs have potential utility in complications arising from a COVID-19 infection For personal use only Increased global interest in the potential of MSCs to treat complications of COVID-19, representing external validation and early studies demonstrating potential utility1 COVID-19 is a respirator
Slide 7: COVID-19 clinical program underpinned by strong pre-clinical and clinical results
Cynata’s COVID-19 clinical development program is underpinned by strong pre-clinical and clinical results For personal use only Cynata’s data supports utility of Compelling pre-clinical results in diseases Cymerus MSCs, confirming that which can arise from a COVID-19 they: infection: Study demonstra
Slide 8: MEND trial: Overview of Phase 2 clinical trial in COVID-19 patients
MEND trial | Overview of Phase 2 clinical trial COVID-19 patients For personal use only Target 24 adult patients with COVID-19 admitted to intensive care with compromised lung function, population which can ultimately progress to ARDS Respiratory distress (+ CRS and sepsis) represent significant
Slide 9: Cymerus platform has potential applications across a wide range of diseases
Cynata's Cymerus platform has potential applications across a wide range of diseases For personal use only Crohn’s CYP-001: Graft vs Disease Others Host Disease Fistula (GvHD) Coronary Artery Potential future Disease Licensed target areas Phase 2 late ‘20 Diabetic wounds Osteoarthritis (funded by
Slide 10: Cynata is targeting significant market opportunities
Cynata is targeting significant market opportunities For personal use only TARGET AREA TRIAL PHASE MARKET OPPORTUNITY Graft vs. Host Disease (GvHD)1 US$0.3 bn Clinical Critical limb Phase 2 US$1.4 bn ischemia (CLI)2 ready Osteoarthritis (OA)3 US$11.6 bn Acute respiratory distress syndrome US$2.5 bn
Slide 11: Cynata is well placed amid expected MSC marketing approvals globally
Cynata is well placed amid expected MSC marketing approvals globally ~30 Phase 3 trials with MSC- Cynata is uniquely placed in the For personal use only based therapies currently active MSC-based therapy market Graft vs. Host Disease (GvHD) Many ongoing Phase 3 trials involve Indications include: ve
Slide 12: Conventional vs. Cynata's Cymerus MSC manufacturing process
Conventional vs. Cynata’s Cymerus MSC manufacturing process Current conventional MSC manufacturing process is impractical For personal use only Cells donated Conventional process MSCs Cells from Cellular therapies MSC isolation MSC expansion multiple donors administered Substantial variability Limit
Slide 13: Only platform able to produce commercial quantities of MSCs from a single source
Cynata has the only platform in the world able to produce commercial quantities of MSCs from a single source Conventional For personal use only Cymerus™ Significance for Cynata process Continuous supply of new One donor, one time Lower cost; simplified logistics; 1 Donors donors required (complete
Slide 14: World-first iPSC-derived cell therapy trial in steroid-resistant acute GvHD completed
World-first allogeneic iPSC-derived cell therapy clinical trial in steroid-resistant acute GvHD completed, with compelling results For personal use only Phase 1 Clinical trial design Key clinical trial results Adults with steroid resistant All 87% 53% ≥87% acute graft-versus-host endpoints disease
Slide 15: Successful clinical data places Cynata in a strong position
Successful clinical data places Cynata in a strong position For personal use only Successful study data Accelerates clinical development Demonstrating efficacy of our Unlocks multiple indications and an technology platform accelerated clinical development pathway Successful clinical results; all e
Slide 16: Executing on a clear scientific and commercial vision
Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value Multiple options to create For personal use only shareholder value case study Build value in platform independently Exclusive global licence in GvHD (e.g. continue runnin
Slide 17: Investment Summary
Investment Summary For personal use only Scalable, Cymerus platform technology enables commercial-scale production of mesenchymal stem cells globally Fully patented process overcomes multiple issues with today’s on-market solutions applicable technology Value of platform to a range of diseases
Slide 18: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 62 Lygon Street ross.macdonald@cynata.com Carlton Victoria 3053 www.cynata.com Australia
Cynata Therapeutics — Investor Presentation (June 2020) on 6ix